Publications by authors named "Nathan Cherny"

Claim this Profile
S
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials.
Cecilie D Amdal, Ragnhild S Falk, Ahu Alanya, Michael Schlichting, Satrajit Roychoudhury, Nathan Cherny

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality.
Maureen E Canavan, Lee Cheng, Jenny Jing Xiang, John Kent Lin, David Hui, Nathan Cherny

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer.
Ian F Tannock, Madeline Lee Pe, Christopher M Booth, Michael Brundage, Nathan I Cherny

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for discussants of randomized cancer trials at major meetings.
Elizabeth A Eisenhauer, Omar Abdihamid, Christopher M Booth, Nathan Cherny, Antonio T Fojo

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials.
Bishal Gyawali, Elizabeth A Eisenhauer, Winette van der Graaf, Christopher M Booth, Nathan I Cherny

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.
Tomer Meirson, Jonathan Ofer, Noa Zimhony-Nissim, Avital Bareket-Samish, Gal Markel, Nathan Cherny

JAMA Netw Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: An international Delphi study.
Séverine M Surges, Holger Brunsch, Birgit Jaspers, Kathi Apostolidis, Antonella Cardone, Nathan Cherny

Palliat Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethical considerations in the relief of cancer pain.
Nathan I Cherny, Batsheva Ziff-Werman

Support Care Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Large-Scale Implementation of an Electronic Patient-Reported Outcome Remote Monitoring System for Patients on Active Treatment at a Community Cancer Center.
Nathan I Cherny, Christina M Parrinello, Lavi Kwiatkowsky, Jeff Hunnicutt, Thaddeus Beck

JCO Oncol Pract· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?
Nathan I Cherny

Nat Rev Clin Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
Daan Geert Knapen, Nathan I Cherny, Panagiota Zygoura, Nicola Jane Latino, Jean-Yves Douillard

ESMO Open· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, Elisabeth G E de Vries, Urania Dafni, Martine J Piccart

ESMO Open· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The global imperative to make cancer medications affordable.
Nathan I Cherny, Elisabeth G E de Vries

Lancet Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?
John G Gribben, Elisabeth de Vries, Nathan I Cherny, Pieter Sonneveld

Hemasphere· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.
Barbara Kiesewetter, Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni

ESMO Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit.
Urania Dafni, Nathan I Cherny, Elisabeth G E de Vries

JAMA Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Death is inevitable - a bad death is not" report from an international workshop.
Adir Shaulov, Kassim Baddarni, Nathan Cherny, Dorith Shaham, Pesach Shvartzman

Isr J Health Policy Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Alexandru Eniu, Nathan I Cherny, Melanie Bertram, Sumitra Thongprasert, Jean-Yves Douillard

ESMO Open· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ESMO-MCBS: setting the record straight.
Nathan I Cherny, Josep Tabernero, Elisabeth G E de Vries

Lancet Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree.
Nathan I Cherny, Elisabeth G E de Vries, Richard L Schilsky

J Natl Compr Canc Netw· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Nathan I Cherny, Elisabeth G E de Vries, Urania Dafni, Elizabeth Garrett-Mayer, Shannon E McKernin

J Clin Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palliative care: needs of advanced breast cancer patients.
Nathan I Cherny, Shani Paluch-Shimon, Yael Berner-Wygoda

Breast Cancer (Dove Med Press)· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Nathan I Cherny, Urani Dafni, Jan Bogaerts, Nicola J Latino, George Pentheroudakis

J Natl Cancer Inst· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework.
Nathan I Cherny, Elisabeth G E de Vries,

JAMA Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care.
David Hui, Nathan I Cherny, Jimin Wu, Diane Liu, Nicola Jane Latino

ESMO Open· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis